Cargando…

Editorial: Non-Dopaminergic Systems in Parkinson’s Disease

Detalles Bibliográficos
Autores principales:	Miguelez, Cristina, De Deurwaerdère, Philippe, Sgambato, Véronique
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7516253/ https://www.ncbi.nlm.nih.gov/pubmed/33013427 http://dx.doi.org/10.3389/fphar.2020.593822

Ejemplares similares

The Noradrenergic System in Parkinson’s Disease
por: Paredes-Rodriguez, Elena, et al.
Publicado: (2020)

Neuropsychiatric Disorders in Parkinson’s Disease: What Do We Know About the Role of Dopaminergic and Non-dopaminergic Systems?
por: Dujardin, Kathy, et al.
Publicado: (2020)

Advances in non-dopaminergic treatments for Parkinson's disease
por: Stayte, Sandy, et al.
Publicado: (2014)

Endocannabinoid Modulation of Dopaminergic Motor Circuits
por: Morera-Herreras, Teresa, et al.
Publicado: (2012)

Corrigendum: Advances in non-dopaminergic pharmacological treatments of Parkinson's disease
por: Stayte, Sandy, et al.
Publicado: (2014)

Parkinson’s disease, dopaminergic drugs and the plant world
por: Kempster, Peter, et al.
Publicado: (2022)

Dopaminergic Pathway Genes Influence Adverse Events Related to Dopaminergic Treatment in Parkinson's Disease
por: Redenšek, Sara, et al.
Publicado: (2019)

Editorial: Insights on neuroinflammatory response by microglia-targeted pharmacology
por: Raber, Jacob, et al.
Publicado: (2023)

Editorial: Contemporary Perspective on 5-HT(2C) Receptor Function and Its Pharmacological Targeting
por: De Deurwaerdère, Philippe, et al.
Publicado: (2020)

Motor cortico-nigral and cortico-entopeduncular information transmission and its modulation by buspirone in control and after dopaminergic denervation
por: Vegas-Suárez, Sergio, et al.
Publicado: (2022)

Non-dopaminergic Alterations in Depression-Like FSL Rats in Experimental Parkinsonism and L-DOPA Responses
por: Schintu, Nicoletta, et al.
Publicado: (2020)

Editorial: Neuroprotection and Disease Modification in Parkinson’s Disease
por: Otero-Losada, Matilde, et al.
Publicado: (2021)

Imbalanced Dopaminergic Transmission Mediated by Serotonergic Neurons in L-DOPA-Induced Dyskinesia
por: Navailles, Sylvia, et al.
Publicado: (2012)

Lorcaserin Alters Serotonin and Noradrenaline Tissue Content and Their Interaction With Dopamine in the Rat Brain
por: Di Giovanni, Giuseppe, et al.
Publicado: (2020)

Impairment of Serotonergic Transmission by the Antiparkinsonian Drug L-DOPA: Mechanisms and Clinical Implications
por: Miguelez, Cristina, et al.
Publicado: (2017)

Noradrenaline and Parkinson's Disease
por: Delaville, Claire, et al.
Publicado: (2011)

Editorial: Neuroprotection and disease modification in Parkinson’s disease: Volume II
por: Otero-Losada, Matilde, et al.
Publicado: (2023)

Corynoxine Protects Dopaminergic Neurons Through Inducing Autophagy and Diminishing Neuroinflammation in Rotenone-Induced Animal Models of Parkinson’s Disease
por: Chen, Leilei, et al.
Publicado: (2021)

Echinacoside Protects Dopaminergic Neurons Through Regulating IL-6/JAK2/STAT3 Pathway in Parkinson’s Disease Model
por: Yang, Xueping, et al.
Publicado: (2022)

The Cross-Talk Between the Dopaminergic and the Immune System Involved in Schizophrenia
por: Vidal, Pia M., et al.
Publicado: (2020)

Increased Expression of Alpha-, Beta-, and Gamma-Synucleins in Brainstem Regions of a Non-Human Primate Model of Parkinson’s Disease
por: Duperrier, Sandra, et al.
Publicado: (2022)

Therapeutic Challenges of Post-traumatic Stress Disorder: Focus on the Dopaminergic System
por: Torrisi, Sebastiano Alfio, et al.
Publicado: (2019)

Neurobiological and Pharmacological Perspectives of D3 Receptors in Parkinson’s Disease
por: Chagraoui, Abdeslam, et al.
Publicado: (2022)

Contribution of the GABAergic System to Non-Motor Manifestations in Premotor and Early Stages of Parkinson’s Disease
por: Murueta-Goyena, Ane, et al.
Publicado: (2019)

Parkinson's disease and dopaminergic neurons
Publicado: (2012)

Oxymatrine Attenuates Dopaminergic Neuronal Damage and Microglia-Mediated Neuroinflammation Through Cathepsin D-Dependent HMGB1/TLR4/NF-κB Pathway in Parkinson’s Disease
por: Gan, Ping, et al.
Publicado: (2020)

Sequential Loss of LC Noradrenergic and Dopaminergic Neurons Results in a Correlation of Dopaminergic Neuronal Number to Striatal Dopamine Concentration
por: Szot, Patricia, et al.
Publicado: (2012)

Fyn Kinase-Mediated PKCδ Y311 Phosphorylation Induces Dopaminergic Degeneration in Cell Culture and Animal Models: Implications for the Identification of a New Pharmacological Target for Parkinson’s Disease
por: Saminathan, Hariharan, et al.
Publicado: (2021)

The acute and long‐term L‐DOPA effects are independent from changes in the activity of dorsal raphe serotonergic neurons in 6‐OHDA lesioned rats
por: Miguelez, C, et al.
Publicado: (2016)

Editorial: Drugging p53 for non-cancer diseases
por: Jiang, Fan, et al.
Publicado: (2022)

Neuroprotective Effects of Salidroside on Cerebral Ischemia/Reperfusion-Induced Behavioral Impairment Involves the Dopaminergic System
por: Zhong, Zhi-feng, et al.
Publicado: (2019)

Presynaptic dopaminergic terminal imaging and non-motor symptoms assessment of Parkinson’s disease: evidence for dopaminergic basis?
por: Qamar, MA, et al.
Publicado: (2017)

Editorial: Therapeutic Implications for Pregnant Women With Systemic Autoimmune Diseases and Their Children
por: Chighizola, Cecilia Beatrice, et al.
Publicado: (2021)

Parkinson’s Disease, the Dopaminergic Neuron and Gammahydroxybutyrate
por: Mamelak, Mortimer
Publicado: (2018)

Editorial: Natural products as potential therapies for non-alcoholic fatty liver disease
por: Ibrahim, Islam A. A. E. H., et al.
Publicado: (2023)

Characterization and Reliability of [(18)F]2FNQ1P in Cynomolgus Monkeys as a PET Radiotracer for Serotonin 5-HT(6) Receptors
por: Sgambato-Faure, Véronique, et al.
Publicado: (2017)

Striatal But Not Extrastriatal Dopamine Receptors Are Critical to Dopaminergic Motor Stimulation
por: Wang, Yuhan, et al.
Publicado: (2017)

Mechanisms Underlying Dopaminergic Regulation of Nicotine-Induced Kinetic Tremor
por: Kato, Masaki, et al.
Publicado: (2022)

L-DOPA in Parkinson’s Disease: Looking at the “False” Neurotransmitters and Their Meaning
por: Chagraoui, Abdeslam, et al.
Publicado: (2019)

Editorial: Translational Research and Drug Repurposing for Non-Communicable Diseases (NCDs)
por: Akindele, Abidemi J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_guig3lko1f5flk5nvs2657cm91